NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT05544929 2026-01-06A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersNovartisPhase 1 Active not recruiting126 enrolled
NCT03454451 2023-12-21CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersCorvus Pharmaceuticals, Inc.Phase 1 Completed117 enrolled